Predicted protein targets (top 15)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | SPHK2 | Q9NRA0 | 5/20 | 0.38 |
| ▸ | SPHK1 | Q9NYA1 | 5/20 | 0.38 |
| ▸ | KCNH2 | Q12809 | 1/20 | 0.38 |
| ▸ | TSHR | P16473 | 3/20 | 0.37 |
| ▸ | LMNA | P02545 | 2/20 | 0.37 |
| ▸ | RAB9A | P51151 | 1/20 | 0.37 |
| ▸ | MAPT | P10636 | 1/20 | 0.37 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.37 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.37 |
| ▸ | PTPN1 | P18031 | 1/20 | 0.37 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.35 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.35 |
| ▸ | HPGD | P15428 | 1/20 | 0.35 |
| ▸ | ATM | Q13315 | 1/20 | 0.35 |
| ▸ | NPSR1 | Q6W5P4 | 1/20 | 0.35 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL25804839 | 0.92 | SPHK2 (0.39) | SPHK2SPHK1KCNH2TSHRLMNA | |
| SCHEMBL25801780 | 0.90 | SPHK1 (0.43) | SPHK2SPHK1TSHRLMNARAB9A | |
| SCHEMBL25801802 | 0.87 | SPHK1 (0.46) | SPHK2SPHK1 | |
| SCHEMBL25801818 | 0.87 | MEN1 (0.40) | LMNAKMT2A | |
| SCHEMBL25801943 | 0.83 | ACACB (0.45) | TSHRLMNARAB9AMAPTSMN1; SMN2 | |
| SCHEMBL25804667 | 0.82 | SPHK1 (0.43) | SPHK2SPHK1TSHRLMNARAB9A | |
| SCHEMBL25802138 | 0.81 | LMNA (0.48) | TSHRLMNAMAPTMAPK1SMN1; SMN2 | |
| SCHEMBL25801790 | 0.81 | MEN1 (0.34) | LMNAKMT2A | |
| SCHEMBL25802128 | 0.81 | LMNA (0.39) | TSHRLMNARAB9AMAPTMAPK1 | |
| SCHEMBL25801755 | 0.81 | HTT (0.48) | TSHRLMNARAB9AMAPTMAPK1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20230219907-A1 | CARBOXY DERIVATIVES WITH ANTIINFLAMATORY PROPERTIES | SITRYX THERAPEUTICS LIMITED (GB) | 2023-07-13 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20230219907-A1 | CARBOXY DERIVATIVES WITH ANTIINFLAMATORY PROPERTIES | CPA2, RO60, C5AR1 | SPHK2 3631/4885SPHK1 3875/4885KCNH2 4192/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.